CC
ACRS icon

Commodore Capital’s Aclaris Therapeutics ACRS Stock Holding History

Commodore Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-635,000
Closed -$5.14M – 28
2023
Q1 		$5.14M Sell
635,000
-1,245,286
-66% -$15.8M 0.78% 26
2022
Q4 		$29.6M Sell
1,880,286
-530,336
-22% -$8.53M 4.46% 7
2022
Q3 		$37.9M Hold
2,410,622
– – 6.1% 7
2022
Q2 		$33.7M Buy
2,410,622
+95,974
+4% +$1.34M 7.12% 6
2022
Q1 		$39.9M Sell
2,314,648
-357,698
-13% -$4.88M 8.91% 2
2021
Q4 		$38.9M Buy
2,672,346
+482,055
+22% +$7.3M 9% 3
2021
Q3 		$39.4M Buy
2,190,291
+521,304
+31% +$8.36M 10.39% 2
2021
Q2 		$29.3M Buy
1,668,987
+640,903
+62% +$14.6M 10.21% 1
2021
Q1 		$25.9M Sell
1,028,084
-308,191
-23% -$6.03M 10.32% 1
2020
Q4 		$8.65M Buy
+1,336,275
New +$5.64M 4.7% 7

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commodore Capital's ACRS Position: Q2 2023 in Review

Commodore Capital sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 635,000 shares — an estimated $5.14M sold.

Commodore Capital first reported a position in ACRS in Q4 2020 and held it in 10 quarters. The position peaked at $39.9M in Q1 2022. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

  • Commodore Capital reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Commodore Capital sold 635,000 Aclaris Therapeutics shares in Q2 2023, an estimated $5.14M.
  • Commodore Capital first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 10 quarters.
  • Commodore Capital's Aclaris Therapeutics position peaked at $39.9M in Q1 2022.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on Commodore Capital's 13F filing for Q2 2023, filed 14 Aug 2023.